|
|
|
|
|
非在研适应症- |
最高研发阶段临床1/2期 |
首次获批国家/地区- |
首次获批日期- |
靶点- |
作用机制- |
|
|
|
非在研适应症- |
最高研发阶段临床1期 |
首次获批国家/地区- |
首次获批日期- |
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered BW-20829 in subjects with elevated lipoprotein(a)
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered BW-20805 in Healthy Subjects
A Phase 1/2 Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BW-20507 in Healthy Subjects
100 项与 ARGO BIOPHARMA AUSTRALIA PTY LTD 相关的临床结果
0 项与 ARGO BIOPHARMA AUSTRALIA PTY LTD 相关的专利(医药)
100 项与 ARGO BIOPHARMA AUSTRALIA PTY LTD 相关的药物交易
100 项与 ARGO BIOPHARMA AUSTRALIA PTY LTD 相关的转化医学